Forbes Medi-Tech Inc.
OTC Bulletin Board : FMTI

September 15, 2005 08:00 ET

Forbes Medi-Tech Preclinical Study Results Demonstrate Cholesterol-Lowering Effects of FM-VP4/Statin 'Zocor' Combination and Effects on Obesity

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Sept. 15, 2005) - Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) today announced the results from two pre-clinical studies involving the Company's cholesterol-lowering drug, FM-VP4. The first study was designed to assess the effects of Forbes' cholesterol-lowering drug candidate, FM-VP4, in combination with Simvastatin (Zocor)®(i) from Merck (NYSE:MRK), in a rabbit model fed a high fat and cholesterol diet over 28 days. The second study was to determine if FM-VP4 decreased body-weight gain in a mouse model fed on a high-fat diet.

"The FM-VP4/Zocor® study results provide an insight into the development path for FM-VP4 as a candidate for statin combination therapy," said Charles Butt, President and CEO of Forbes Medi-Tech Inc. "The obesity study results demonstrate a significant reduction of weight-gain and help identify FM-VP4's additional therapeutic indications."

The results illustrated that a combination of Zocor® and FM-VP4 reduced total plasma cholesterol, LDL cholesterol, total plasma triglyceride and the LDL cholesterol/HDL ratio more than either Zocor® or FM-VP4 alone. The study conclusion, therefore, is that a combination of Zocor® and FM-VP4 is more effective between 7 and 28 days than either compound alone in reducing plasma lipid levels in this high fat/cholesterol rabbit model.

The obesity study results show a significant difference in weight gain between the high-fat diet versus high-fat diet plus FM-VP4 treatment groups. The results are indicative of potential obesity control beyond the cholesterol-lowering effects of FM-VP4.

The results and conclusions from these studies will be presented at the upcoming American Association of Pharmaceutical Scientists (AAPS) conference in November in Nashville, TN. The abstracts will be posted on the AAPS website on or before the conference.

About FM-VP4

FM-VP4 is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drugs. FM-VP4 has demonstrated significant cholesterol-lowering and anti-atherosclerotic properties in pre-clinical studies. The cardiovascular market represents a significant opportunity as industry-wide sales of cardiovascular pharmaceuticals are estimated to grow to over $40 billion by 2011. (Datamonitor, 2004)

About Forbes Medi-Tech Inc.

Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.

(i) Zocor is a registered trademark owned by Merck & Co., Inc.

This News Release contains forward-looking statements regarding the Company, and its drug candidate, FM-VP4, which statements can be identified by the use of forward-looking terminology such as "vision", "will be", "estimated", "opportunity", "strategy", "will", or comparable terminology referring to future events or results or terminology referring to future dates. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including uncertainty whether FM-VP4 will be developed into a statin combination therapy or otherwise; uncertainty whether results seen in animal studies will be seen to the same extent in future animal or human studies or at all; uncertainty whether FM-VP4 will be successfully commercialized; uncertainty whether the Company will realize is strategies and vision; the need for additional research and development, including clinical trials, the occurrence and success of which is not assured; intellectual property risks; the need for regulatory approvals, which are not assured and which may be denied or withdrawn; manufacturing risks and the need to manufacture to regulatory standards; product liability and insurance risks; the risk of unknown side effects; intellectual property risks; the effect of competition; and the Company's need for future funding; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's reports filed with the Canadian and U.S. securities regulatory authorities from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.

NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release.

Contact Information